HomechapterChapter 39: Drug-Induced Kidney Disease

Chapter 39: Drug-Induced Kidney Disease

Clinical editorial background for Chapter 39: Drug-Induced Kidney Disease - Complete Educational Package
Chapter visual background for web learning and presentation use.

Chapter 39: Drug-Induced Kidney Disease – Complete Educational Package

Learning Objectives

By the end of this chapter, learners will be able to:
1. Identify common drugs that cause kidney injury.
2. Understand the mechanisms of drug-induced kidney disease (DIKD).
3. Recognize the clinical presentations of various forms of DIKD.
4. Discuss strategies for prevention and management of DIKD.
5. Appreciate the importance of medication reconciliation and careful prescribing in patients with kidney disease.

39.1 Introduction to Drug-Induced Kidney Disease (DIKD)

Drug-induced kidney disease (DIKD), also known as drug-induced nephrotoxicity, is a significant cause of acute kidney injury (AKI) and chronic kidney disease (CKD). It can result from various mechanisms, affecting different parts of the nephron, and can range from asymptomatic changes in renal function to severe, life-threatening kidney failure. Understanding the potential nephrotoxic effects of medications is crucial for safe prescribing and patient management.

39.2 Mechanisms of Drug-Induced Kidney Disease

DIKD can occur through several mechanisms, often depending on the specific drug and patient factors.

  • Hemodynamic-Mediated Kidney Injury:
    • Afferent Arteriole Vasoconstriction: Nonsteroidal anti-inflammatory drugs (NSAIDs) and calcineurin inhibitors (CNIs like cyclosporine, tacrolimus) can constrict the afferent arteriole, reducing glomerular filtration pressure and GFR.
    • Efferent Arteriole Vasodilation: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) can dilate the efferent arteriole, reducing glomerular filtration pressure. This is usually beneficial but can cause AKI in patients with pre-existing renal artery stenosis or volume depletion.
  • Acute Tubular Necrosis (ATN): Direct tubular cell toxicity leading to cell death and impaired reabsorption/secretion.
    • Aminoglycosides: Accumulate in proximal tubular cells, causing mitochondrial damage and oxidative stress.
    • Amphotericin B: Directly toxic to tubular cells and causes renal vasoconstriction.
    • Cisplatin: Accumulates in proximal tubules, leading to oxidative stress and apoptosis.
    • Radiocontrast Media: Direct tubular toxicity and renal vasoconstriction.
  • Acute Interstitial Nephritis (AIN): An immune-mediated inflammatory reaction in the renal interstitium.
    • Beta-lactam antibiotics (e.g., penicillin, cephalosporins): Most common cause.
    • NSAIDs: Can cause AIN, often with nephrotic-range proteinuria.
    • Proton Pump Inhibitors (PPIs): Increasingly recognized cause.
    • Sulfonamides, allopurinol, rifampin.
  • Glomerular Disease:
    • Minimal Change Disease/FSGS: NSAIDs, lithium, pamidronate.
    • Membranous Nephropathy: Gold, penicillamine, NSAIDs.
  • Obstructive Nephropathy (Intratubular Obstruction): Precipitation of drugs or their metabolites within the renal tubules.
    • Acyclovir, indinavir, methotrexate, sulfonamides.
  • Crystal Nephropathy: Precipitation of drug crystals in the tubules.
    • Sulfonamides, methotrexate, indinavir, acyclovir.
  • Thrombotic Microangiopathy (TMA): Drug-induced damage to endothelial cells, leading to microvascular thrombosis.
    • Calcineurin inhibitors, quinine, ticlopidine, clopidogrel, gemcitabine.

39.3 Clinical Presentation

The clinical presentation of DIKD varies depending on the mechanism and severity of injury.

  • AKI: Most common presentation, characterized by an acute rise in serum creatinine and/or decrease in urine output.
  • AIN: Often presents with fever, rash, eosinophilia, and sterile pyuria, though these classic signs are absent in many cases. Renal dysfunction can be acute or subacute.
  • ATN: Non-oliguric or oliguric AKI, often with muddy brown granular casts in urine sediment.
  • Glomerular Disease: Proteinuria, hematuria, edema, hypertension.
  • Obstructive Nephropathy: Flank pain, hematuria, oliguria.

39.4 Diagnosis of DIKD

Diagnosis relies on a high index of suspicion, careful medication history, and exclusion of other causes of kidney injury.

  • Detailed Medication History: Crucial to identify recently started or changed medications, including over-the-counter drugs, herbal supplements, and illicit substances.
  • Temporal Relationship: Onset of kidney injury after drug initiation.
  • De-challenge: Improvement in renal function after drug discontinuation.
  • Re-challenge: Worsening of renal function upon re-exposure to the drug (generally not recommended due to risk).
  • Laboratory Tests: Serum creatinine, BUN, electrolytes, urinalysis (casts, proteinuria, hematuria, eosinophiluria).
  • Renal Biopsy: May be necessary for definitive diagnosis, especially in AIN or glomerular forms of DIKD.

39.5 Prevention and Management

Prevention is key in DIKD. Management involves drug discontinuation and supportive care.

Prevention Strategies:

  • Avoid Nephrotoxic Drugs: When possible, use alternative medications.
  • Adjust Dosing: Dose adjustment for drugs primarily cleared by the kidneys, especially in patients with pre-existing CKD.
  • Assess Risk Factors: Identify patients at higher risk (e.g., elderly, pre-existing CKD, diabetes, heart failure, volume depletion, multiple nephrotoxic drugs).
  • Maintain Hydration: Ensure adequate hydration, especially before contrast administration or with drugs like cisplatin.
  • Monitor Renal Function: Regular monitoring of serum creatinine and urine output in patients receiving nephrotoxic drugs.

Management:

  • Discontinue the Offending Drug: The most important step.
  • Supportive Care: Fluid and electrolyte management, blood pressure control, management of complications of AKI.
  • Corticosteroids: May be considered in severe cases of AIN, though evidence is not conclusive.
  • Renal Replacement Therapy: If severe AKI develops and is unresponsive to conservative measures.

Key Points on Drug-Induced Kidney Disease

  1. Definition: Kidney injury caused by medications, ranging from mild dysfunction to severe failure.
  2. Mechanisms: Hemodynamic changes (NSAIDs, ACEi/ARBs), direct tubular toxicity (aminoglycosides, amphotericin B, cisplatin, contrast), AIN (antibiotics, NSAIDs, PPIs), glomerular disease, obstruction, TMA.
  3. Presentation: Most commonly AKI; AIN can have fever, rash, eosinophilia; ATN with muddy brown casts.
  4. Diagnosis: High suspicion, detailed drug history, temporal relationship, de-challenge, laboratory tests, sometimes biopsy.
  5. Prevention: Avoid nephrotoxins, dose adjust, assess risk, hydrate, monitor.
  6. Management: Discontinue drug, supportive care, sometimes steroids for AIN, RRT if severe.

DIKD Quick Guide

  • Drugs Hurt Kidneys: Many common meds can cause kidney damage.
  • Watch for AKI: Sudden creatinine rise is a red flag.
  • Know the Culprits: NSAIDs, ACEi/ARBs, certain antibiotics, contrast, PPIs.
  • Stop the Drug: First and most important step.
  • Hydrate & Monitor: Best prevention strategies.

Diagnostic Pearls

  1. Hidden Nephrotoxins: Always ask about over-the-counter medications, herbal supplements, and illicit drugs when investigating AKI, as patients may not consider them

Clinical Pearls and Review

Clinical Pearls

Diagnostic Pearls

  1. Always ask about over-the-counter analgesics, supplements, herbal products and recent short courses of medication when evaluating AKI.
  2. A temporal relationship supports DIKD but does not prove it; review volume status, infection, obstruction, hemodynamics and other competing diagnoses.
  3. Classic AIN features such as fever, rash and eosinophilia may be absent, so urinalysis and medication chronology remain important.

Management Pearls

  1. Stop the suspected offending drug when clinically safe and document the reaction to prevent inadvertent re-exposure.
  2. Adjust doses of renally cleared medicines as kidney function changes, and monitor creatinine, electrolytes and urine output.
  3. Consult nephrology when AKI is severe, diagnosis is uncertain, glomerular disease is suspected or kidney replacement therapy may be required.

Visual Materials

  • Mechanism map linking hemodynamic injury, tubular toxicity, interstitial nephritis, crystal injury, obstruction and thrombotic microangiopathy to representative drugs.
  • Medication-reconciliation checklist for new AKI, including prescription, over-the-counter, herbal and contrast exposures.
  • Management workflow from recognition and drug withdrawal through supportive care, monitoring and escalation.

Multiple-Choice Questions

Question 1

A patient develops AKI two weeks after starting a proton-pump inhibitor. Fever and rash are absent. Which next step is most appropriate?

  1. Ignore the medication because classic AIN features are absent.
  2. Review the medication chronology, urinalysis and competing causes, and stop the drug if clinically safe.
  3. Restart the drug to confirm causality.
  4. Give contrast imaging without assessing kidney function.

Answer: B. AIN often lacks the full classic triad; a structured medication review and evaluation for alternative causes are essential.

Question 2

Which intervention is most important when a nephrotoxic drug is strongly suspected and no longer essential?

  1. Continue it at the same dose until biopsy is performed.
  2. Discontinue it safely and provide supportive monitoring.
  3. Double the dose to shorten exposure.
  4. Restrict all fluids regardless of volume status.

Answer: B. Safe withdrawal of the suspected agent and supportive management are central to preventing further injury.

Visual learning: Chapter 39: Drug-Induced Kidney Disease – Complete Educational Package

Clinical workflow diagram for Chapter 39: Drug-Induced Kidney Disease - Complete Educational Package
Structured clinical workflow diagram. Use this visual as a review aid; it does not replace individualized clinical judgment.

Presentation resource: The Kidney Hub clinical-series PowerPoint for Chapters 31–40 accompanies these chapters for teaching use.

▶ Open Chapter 39 PowerPoint Presentation
Sign Up